GlassScriptPhysician profile
Linda G Widner
NPI 1265430250
$5,851.26
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,833 · 2022: $1,384 · 2023: $1,271 · 2024: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,005.13 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $709.12 | 2021-2024 | Prolia, Repatha, Otezla |
| Novo Nordisk INC | $631.39 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.22 | 2021-2024 | Jardiance, Synjardy |
| Pfizer INC. | $382.37 | 2021-2024 | |
| Amarin Pharma, INC. | $366.57 | 2021-2022 | |
| Lilly USA, LLC | $339.99 | 2021-2024 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $288.17 | 2021-2024 | |
| Abbvie INC. | $278.99 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $215.82 | 2022-2024 | |
| Esperion Therapeutics, INC. | $182.69 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.11 | 2022 | |
| Exact Sciences Corporation | $139.56 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $131.92 | 2021-2024 | Shingrix, Arexvy |
| Daiichi Sankyo INC. | $109.04 | 2021-2024 | Injectafer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.68 | 2022-2023 | Verquvo, Steglatro, Steglujan |
| Kowa Pharmaceuticals America, INC. | $51.88 | 2021-2023 | Seglentis, Livalo |
| Paratek Pharmaceuticals, INC. | $45.87 | 2021 | |
| Dexcom, INC. | $42.54 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $31.91 | 2022 | |
| Sumitomo Pharma America, INC. | $28.18 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $23.06 | 2021 | |
| Ibsa Pharma INC. | $22.02 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.88 | 2022 | |
| Kyowa Kirin, INC. | $20.69 | 2023 | Crysvita |
| Medtronic, INC. | $20.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Widner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.